Phase 1 Advanced Unresectable Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Advanced Unresectable or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.528 enrolled1 locationNCT06555068
Recruiting
Phase 1
SG1906 for CLDN18.2-Positive Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.60 enrolled9 locationsNCT05857332
Recruiting
Phase 1Phase 2
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
NEOK Bio, Inc.155 enrolled8 locationsNCT07612189
Recruiting
Phase 1
A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
NEOK Bio, Inc.155 enrolled8 locationsNCT07612176
Recruiting
Phase 1
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Advanced Unresectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.36 enrolled2 locationsNCT07478302
Recruiting
Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled39 locationsNCT05458219
Recruiting
Phase 1Phase 2
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
MetastaticAdvanced Unresectable
Beijing Biotech72 enrolled1 locationNCT07523529
Recruiting
Phase 1Phase 2
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Advanced Unresectable or Metastatic Breast Cancer of Adults
Shandong Suncadia Medicine Co., Ltd.180 enrolled2 locationsNCT07389733
Recruiting
Phase 1Phase 2
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.300 enrolled2 locationsNCT06679036
Recruiting
Phase 1
Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma
Locally Advanced Unresectable Pancreatic Adenocarcinoma
Impact Biotech Ltd30 enrolled2 locationsNCT05919238
Recruiting
Phase 1
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Phase 1
A Study of TXN10128 in Subjects With Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Txinno Bioscience Inc.96 enrolled6 locationsNCT05978492
Recruiting
Phase 1Phase 2
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.368 enrolled6 locationsNCT05636215
Recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Metastatic Solid TumorAdvanced Unresectable Solid Tumor
TopAlliance Biosciences499 enrolled24 locationsNCT04137900